Novartis Oncology: Patient Assistance Now Oncology

Patient Support Services Guide 2018


Novartis Patient Assistance NOW
800-245-5356
Universal Co-Pay Program
800-282-7630

Novartis Oncology provides a full range of patient assistance programs and support services, through Novartis Patient Assistance Now Oncology (PANO). This comprehensive support program provides support and resources for patients and providers through the Novartis Universal Co-Pay Program, Novartis Patient Assistance Foundation.

In addition, drug-specific programs are available for some of Novartis Oncology medications, including Kisqali Care, Kymriah Cares, and Rydapt NOW.

The list of Novartis Oncology medicines, their indications, and their respective support programs is provided in the Table.

The Novartis PANO platform is a comprehensive oncology resource that provides information on patient assistance, including reimbursement and support programs. These support options include insurance verification, education on Medicare, and information about financial assistance and free medication programs. For more information about accessing support, visit HCP.Novartis.com/access.

Novartis Patient Assistance Foundation

Patients with financial hardship who have no third-party insurance coverage for their Novartis medicines may be eligible to receive the drugs at no cost.

Universal Co-Pay Program

Patients with commercial insurance or patients paying cash without government-funded insurance may be eligible for copay assistance.

Providers can visit HCP.Novartis.com/access or call 800-282-7630 for assistance with the reimbursement process for Novartis Oncology drugs. Services include insurance benefits and coverage verification, copayment clarifications, assistance with coding and billing questions, denials and appeals support, as well as alternative funding searches and referrals to Novartis Oncology brand-specific copay card programs and independent assistance programs.

Kisqali Care

This comprehensive patient support program provides access to Kisqali (ribociclib) tablets for patients with commercial insurance who are prescribed Kisqali.

Kymriah Cares

For patients who are prescribed Kymriah (tisagenlecleucel), Kymriah Cares provides information on financial assistance and patient support programs, including insurance coverage, and offers resources to help throughout treatment.

Rydapt NOW

This program provides support to patients who are prescribed Rydapt (midostaurin) capsules. Care coordinators provide patients access to a clinical educator and information about financial assistance.

Eligibility

Patients looking for financial assistance for a Novartis Oncology medication can visit this website to check their eligibility based on their insurance status.

Novartis Universal Co-Pay Program

The enrollment requirements for this drug-specific program vary by medication. To enroll in a specific drug program, visit CoPay.NovartisOncology.com and select the prescribed medication, or call 877-577-7756.

To be eligible for the Novartis Universal Co-Pay Program, patients must:

  • Have commercial insurance; those with public insurance are not eligible
  • Be a resident of the United States and have a qualified Novartis medication prescribed for an approved indication.

Eligible patients will pay up to $25 monthly out of pocket, depending on the medication, with a maximum annual benefit of $15,000 for medications.

Gleevec $10 Co-Pay Card

Patients with commercial insurance who are prescribed Gleevec (imatinib mesylate) may be eligible for the Gleevec $10 Co-Pay Card. Eligible patients will pay the first $10 for a 30-day supply of Gleevec, and the program will pay ≤$10,630 for a 30-day supply, with an annual maximum of $30,000.

Kisqali Care

Commercially insured patients who are experiencing coverage delays for Kisqali may be eligible for the Kisqali 5-Treatment Cycle Access Program, which provides:

  • ≤5 free treatment cycles of Kisqali
  • A voucher for 1 free treatment cycle of Kisqali, available online or by calling 800-282-7630
  • Educational information about Kisqali, insurance coverage, and financial assistance, as well as access to a dedicated navigator who will provide 1-on-1 assistance.

Rydapt NOW

Patients who have been prescribed Rydapt for an FDA-approved indication and are new to therapy or are experiencing insurance coverage delay may be eligible to receive 1 free cycle of Rydapt through the Rydapt NOW Access Program or the Rydapt NOW Free Supply Program. Rydapt NOW also provides eligible patients access to Care Coordinators who will provide help in investigating the patient benefits about access to Rydapt, and help with insurance verification, prior authorizations, and finding a pharmacy in their health plan.

Tasigna 3 Months Free Trial Voucher

Eligible patients with a valid prescription for Tasigna (nilotinib) may be able to receive 3 months of medication for free by using the Tasigna 3 Months Free Trial Voucher.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Novartis Oncology medication for free through this foundation. Eligible patients will receive the medication for free for 1 year, or until a prescription drug coverage becomes available to them. To be eligible for this program, the patient must:

  • Be a citizen of the United States
  • Have an annual household income of ≤$75,000 for 1 person; ≤$100,000 for 2 people; ≤$125,000 for 3 people; ≤$150,000 for 4 people; and ≤$25,000 more for each additional person in the household.

Application & Enrollment

Universal Co-Pay Program

Enrollment for copay assistance is also medication-specific. In some cases, a copay card can be downloaded and printed from the drug’s website; for some drugs, patients may be required to complete a copay assistance enrollment form and provide it to the specialty pharmacy.

Novartis Patient Assistance Foundation

The enrollment process varies by medication. To learn more about the application process for a specific prescribed medication, visit this website or call 800-277-2254.

By selecting the medication from the list, applicants can access enrollment information that is specific to the particular drug.

Table Novartis Oncology/Oncology Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Afinitor (everolimus)
Indication
Advanced HR-positive, HER2-negative breast cancer; advanced kidney cancer; advanced neuroendocrine tumors of gastrointestinal or lung origin; renal angiomyolipoma with TSC; subependymal giant-cell astrocytoma with TSC

Drug
Arranon (nelarabine)
Indication
T-cell acute lymphoblastic leukemia; T-cell lymphoblastic lymphoma
Patient support program

Drug
Arzerra (ofatumumab)
Indication
Recurrent or progressive chronic lymphocytic leukemia
Patient support program

Drug
Exjade (deferasirox)
Indication
Chronic iron overload caused by blood transfusions

Drug
Farydak (panobinostat)
Indication
Multiple myeloma, in combination with bortezomib and dexamethasone

Drug
Gleevec (imatinib mesylate)
Indication
Ph+ chronic myeloid leukemia; Ph+ acute lymphoblastic leukemia; myelodysplastic or myeloproliferative diseases; aggressive systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia; unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans; CD117-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors

Drug
Hycamtin capsules (topotecan)
Indication
Relapsed small-cell lung cancer
Patient support program

Drug
Hycamtin for injection (topotecan hydrochloride)
Indication
Metastatic carcinoma of the ovary; small-cell lung cancer; recurrent or persistent carcinoma of the cervix
Patient support program

Drug
Jadenu (defarasirox) tablets
Indication
Chronic iron overload caused by blood transfusions

Drug
Kisqali (ribociclib) tablets
Indication
HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy, in combination with an aromatase inhibitor

Drug
Kymriah (tisagenlecleucel)
Indication
Relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Patient support program

Drug
Mekinist (trametinib)
Also in combination with Tafinlar
Indication
Unresectable or metastatic melanoma with BRAF V600E or V600K mutation, alone or in combination with Tafinlar; metastatic NSCLC with BRAF V600E mutation, in combination with Tafinlar

Drug
Promacta (eltrombopag)
Indication
Chronic immune (idiopathic) thrombocytopenia; severe aplastic anemia

Drug
Rydapt (midostaurin) capsules
Indication
Newly diagnosed acute myeloid leukemia with FLT3 mutation, in combination with cytarabine and daunorubicin induction and cytarabine consolidation; aggressive systemic mastocytosis, systemic mastocytosis with hematologic neoplasm, or mast-cell leukemia

Drug
Sandostatin LAR Depot (octreotide acetate for injectable suspension)
Indication
Severe diarrhea or flushing episodes in metastatic carcinoid or VIP-secreting tumors; acromegaly

Drug
Tafinlar (dabrafenib)
Also in combination with Mekinist
Indication
Unresectable or metastatic melanoma with BRAF V600E or V600K mutation, alone or with Mekinist; metastatic NSCLC with BRAF V600E mutation, with Mekinist

Drug
Tasigna (nilotinib)
Indication
Ph+ chronic myeloid leukemia

Drug
Tykerb (lapatinib)
Indication
HER2/neu advanced or metastatic breast cancer

Drug
Votrient (pazopanib)
Indication
Advanced renal-cell carcinoma; advanced soft-tissue sarcoma

Drug
Zometa (zoledronic acid)
Indication
Bone loss caused by cancer
Patient support program

Drug
Zykadia (ceritinib)
Indication
Metastatic NSCLC with ALK mutation

HR indicates hormone receptor; NSCLC, non–small-cell lung cancer; Ph+, Philadelphia chromosome–positive; TSC, tuberous sclerosis complex; VIP, vasoactive intestinal peptide.